| Literature DB >> 31100974 |
Marek Paździor1, Małgorzata Kiełczykowska2, Jacek Kurzepa3, Dorota Luchowska-Kocot4, Joanna Kocot5, Irena Musik6.
Abstract
Background and Objective: Osteoarthritis (OA) is a disorder of the musculoskeletal system resulting in worsening of life condition. The research revealed the involvement of oxidative stress into both OA pathogenesis and the effects of therapeutic agents applied in OA cases. The activities of the most important antioxidant enzymes, namely superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) and total antioxidant status (TAS), in blood of the knee OA patients were studied, with the aim of clarifying which enzymatic antioxidants are involved into osteoarthritis (OA)-related oxidative stress and whether any compensatory effects occur. The results were additionally analyzed with regard to gender.Entities:
Keywords: catalase; gender; glutathione peroxidase; knee OA; superoxide dismutase; total antioxidant status
Mesh:
Substances:
Year: 2019 PMID: 31100974 PMCID: PMC6572222 DOI: 10.3390/medicina55050150
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Clinical data and antioxidative parameters of OA (osteoarthritis) patients and control subjects.
| Parameters | Control | OA Patients |
|
|---|---|---|---|
| Clinical Parameters | |||
| WBC (109/L) | 6.57 ± 1.24 | 7.09 ± 1.80 | 0.21738 (t) |
| RBC (1012/L) | 4.55 ± 0.64 | 4.47 ± 0.51 | 0.52731 (t) |
| HGB (g/dL) | 14.0 (12.4–15.2) | 14.0 (12.2–14.5) | 0.22108 (U) |
| HCT (%) | 39.7 ± 4.9 | 39.2 ± 4.1 | 0.60931 (t) |
| MCV (fL) | 87.1 ± 3.2 | 88.0 ± 4.9 | 0.41259 (t) |
| MCH (pg) | 29.7 ± 1.4 | 29.7 ± 2.0 | 0.97653 (t) |
| MCHC (g/dL) | 34.2 ± 1.2 | 33.7 ± 1.1 | 0.10841 (t) |
| RDW-CV (%) | 13.1 (12.6–13.7) | 13.6 * (12.9–14.2) | 0.03887 (U) |
| PLT (109/L) | 225 (195–254) | 233 (204–261) | 0.36004 (U) |
| PDW (%) | 11.4 (10.8–13.9) | 11.7 (11.0–13.0) | 0.95706 (U) |
| MPV (fL) | 10.0 (9.8–11.1) | 10.3 (9.8–11.0) | 0.70990 (U) |
| P-LCR (%) | 28.9 ± 7.6 | 28.7 ± 6.8 | 0.91403 (t) |
| PCT (%) | 0.25 (0.20–0.26) | 0.25 (0.21–0.28) | 0.51190 (U) |
| Antioxidant Parameters | |||
| TAS (mmol/L) | 4.70 ± 0.60 | 4.39 ± 0.53 * | 0.02626 (t) |
| GPx (U/L) | 675 ± 149 | 518 ± 176 *** | 0.00042 (t) |
| SOD(U/mL) | 127 ± 42 | 109 ± 32 * | 0.04224 (t) |
| CAT (U/mL) | 23.3(14.0–37.0) | 22,1 (11.6–34.9) | 0.82567 (U) |
Values are mean ± SD for normally distributed variables while non-normally distributed ones are expressed as median and interquartile range. (t), t-Student test; (U), U Mann–Whitney test; * p < 0.05 vs. control; *** p < 0.001 vs. control. WBC, white blood cells; RBC, red blood cells; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW-CV, red blood cell distribution width, coefficient of variation; PLT, platelets; PDW, platelet distribution width; MPV, mean platelet volume; P-LCR, platelet large cell ratio; PCT, plateletcrit; TAS, total antioxidant status; GPx, glutathione peroxidase; SOD, superoxide dismutase; CAT, catalase.
Clinical data of OA patients and control subjects with regard to gender.
| Parameter | C-Male | C-Female | OA-Male | OA-Female |
|---|---|---|---|---|
| WBC (109/L) (HSD) | 6.30 ± 0.84 a | 6.86 ± 1.56 a | 7.32 ± 1.63 a | 7.01 ± 1.87 a |
| RBC (1012/L) (HSD) | 5.06 ± 0.23 a | 3.99 ± 0.45 b | 4.79 ± 0.47 a | 4.35 ± 0.48 b |
| HGB (g/dL) | 15.2 | 12.3 | 14.9 | 13.0 |
| (KW) | (14.9–15.5) a | (11.9–12.5) b | (13.9–15.3) a | (11.8–13.7) b |
| HCT (%) (HSD) | 43.4 ± 1.7 a | 35.8 ± 4.2 b | 42.3 ± 3.3 a | 38.1 ± 3.7 b |
| MCV (fL) (HSD) | 85.6 ± 1.7 a | 88.7 ± 3.6 a | 88.7 ± 4.7 a | 87.8 ± 5.0 a |
| MCH (pg) | 29.7 | 29.1 | 30.5 | 29.5 |
| (KW) | (29.5–30.1) a | (28.7–39.0) a | (28.9–31.7) a | (28.1–31.0) a |
| MCHC (g/dL) | 35.0 | 33.5 | 34.3 | 33.6 |
| (KW) | (34.6–35.2) a | (32.7–34.1) b | (34.0–35.1) a | (33.0–34.1) b |
| RDW-CV (%) | 12.6 | 13.7 | 13.5 | 13.7 |
| (KW) | (12.4–13.1) a | (13.1–14.2) a,b | (12.9–14.2) a,b | (12.9–14.1) b |
| PLT (109/L] | 246 | 205 | 210 | 239 |
| (KW) | (195–258] a | (194–230] a | (180–233) a | (221–264) a |
| PDW (%] | 11.4 | 11.7 | 11.7 | 11.7 |
| (KW) | (10.6–15.0) a | (10.9–13.9) a | (10.9–12.8) a | (11.1–13.0) a |
| MPV (fL] | 10.0 | 10.0 | 10.1 | 10.3 |
| (KW) | (9.5–11.4] a | (9.9–11.1) a | (9.8–10.9) a | (9.8–11.0) a |
| P-LCR (%] | 25.5 | 26.4 | 26.2 | 28.0 |
| (KW) | (21.6–35.8] a | (24.3–34.8] a | (23.4–31.7) a | (24.9–33.2) a |
| PCT (%] | 0.25 | 0.24 | 0.21 | 0.26 |
| (KW) | (0.18–0.26) a,b | (0.20–0.27) a,b | (0.19–0.24) a | (0.23–0.28) b |
Values are mean ± SD for normally distributed variables while non-normally distributed ones are expressed as median and interquartile range. (HSD), Tukey’s honest significant difference test; (KW), Kruskal–Wallis test. The values in rows sharing the same superscript are not statistically significant. WBC, white blood cells; RBC, red blood cells; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW-CV, red blood cell distribution width, coefficient of variation; PLT, platelets; PDW, platelet distribution width; MPV, mean platelet volume; P-LCR, platelet large cell ratio; PCT, plateletcrit.
Antioxidant parameters in OA patients and control subjects with regard to gender.
| Parameter | C-Male | OA-Male | C-Female | OA-Female |
|---|---|---|---|---|
| TAS (mmol/L) (HSD) | 4.41 ± 0.52 a | 4.61 ± 0.54 a,c | 5.02 ± 0.54 b,c | 4.31 ± 0.51 a |
| GPx (U/L) (HSD) | 715 ± 105 a | 482 ± 185 b,c | 630 ± 181 a,c | 532 ± 173 a,c |
| SOD (U/mL) (HSD) | 127 ± 39 a | 115 ± 22 a | 127 ± 48 a | 107 ± 35 a |
| CAT (U/mL) | 14.0 | 26.9 | 38.5 | 20.2 |
| (KW) | (7.0–18.6) a | (23.3–46.5) b,d | (27.9–46.6) c,d | (11.6–31.6) a,b |
Values are mean ± SD for normally distributed variables while non-normally distributed ones are expressed as median and interquartile range. (HSD), Tukey’s honest significant difference test; (KW), Kruskal–Wallis test. The values in rows sharing the same superscript are not statistically significant.